Citadel Advisors’s CollPlant Biotechnologies CLGN Stock Holding History

Citadel Advisors’s Portfolio CLGN Stock Details CLGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$17.2K	Buy	+32,165	New	+$32.5K	﹤0.01%	12700
2024 Q2	–	Sell	-13,193	Closed	-$71.1K	–	14362
2024 Q1	$71.1K	Buy	13,193 +6,459	+96%	+$34.9K	﹤0.01%	11799
2023 Q4	$43K	Buy	+6,734	New	+$36.8K	﹤0.01%	11940
2021 Q3	–	Sell	-13,034	Closed	-$276K	–	13859
2021 Q2	$276K	Buy	+13,034	New	+$208K	﹤0.01%	11461
2021 Q1	–	Sell	-11,937	Closed	-$126K	–	13203
2020 Q4	$126K	Buy	11,937 +971	+9%	+$7.84K	﹤0.01%	10061
2020 Q3	$88K	Buy	+10,966	New	+$98.6K	﹤0.01%	9345
2019 Q3	–	Sell	-11,119	Closed	-$44K	–	9206
2019 Q2	$44K	Buy	+11,119	New	+$58.4K	﹤0.01%	8761
2018 Q4	–	Sell	-13,885	Closed	-$72K	–	9155
2018 Q3	$72K	Buy	+13,885	New	+$76.5K	﹤0.01%	8697

Other funds holding CLGN

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

LWMI

Legacy Wealth Management (Idaho) Boise, Idaho $201M AUM 259.85% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

WPC

Waters Parkerson & Co New Orleans, Louisiana $1.95B AUM 15.9% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Citadel Advisors's CLGN Position: Q1 2026 in Review

Citadel Advisors opened a new position in CollPlant Biotechnologies (CLGN) in Q1 2026: 32,165 shares worth $17.2K. The stake represents ﹤0.01% of the portfolio and ranks #12700 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in CLGN as recently as Q1 2024.

Citadel Advisors first reported a position in CLGN in Q3 2018 and has held it in 8 quarters since. The position peaked at $276K in Q2 2021. 21 funds tracked by Wall St. Rank hold CLGN as of Q1 2026.

Citadel Advisors held 32,165 shares of CollPlant Biotechnologies worth $17.2K as of Q1 2026.
CollPlant Biotechnologies was a new Citadel Advisors position in Q1 2026.
CollPlant Biotechnologies made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12700 holding.
Citadel Advisors first reported a position in CollPlant Biotechnologies in Q3 2018 and has held it in 8 quarters since.
Citadel Advisors's CollPlant Biotechnologies position peaked at $276K in Q2 2021.
21 funds tracked by Wall St. Rank held CollPlant Biotechnologies as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.